# Guillaume Pfefer

> Boston-based biotech executive Guillaume Pfefer is the founder and managing partner of NextBio LLC, whose public website lists him as CEO. His career includes leadership at Sanofi Pasteur Mexico, Kala Pharmaceuticals, GSK, Senda Biosciences and Sail Biomedicines, alongside a former CEO-Partner role at Flagship Pioneering. His engineering, scientific and business training accompanies a management approach centered on collaboration and developing colleagues.

- **Role:** Founder and Managing Partner at NextBio LLC; listed as CEO on the company website
- **Organizations:** NextBio LLC, Prota Therapeutics (director), Sail Biomedicines (former CEO), Senda Biosciences (former CEO), Flagship Pioneering (former CEO-Partner), GSK, Kala Pharmaceuticals, Sanofi Pasteur, Aventis, Rhône-Poulenc
- **Education:** Master’s degree in Chemical Engineering, National School for Chemical Engineering, Nancy, France, PhD in Materials Science, Centre National de la Recherche Scientifique (CNRS), France, MBA; Finance and Entrepreneurship majors, The Wharton School, University of Pennsylvania
- **Known for:** Named to the 2021 PharmaVOICE 100., Led organizations across multinational pharmaceutical companies and emerging biotech businesses., Appointed founding CEO of Sail Biomedicines following the 2023 combination of Senda and Laronde.

## Career timeline

- **Before 2012** — Executive roles at Rhône-Poulenc and Aventis, followed by leadership at Sanofi Pasteur, including general manager in Mexico.
- **2012** — Appointed president, CEO and board member of Kala Pharmaceuticals on July 12.
- **Before July 2020** — Served as senior vice president and global leader at GSK.
- **2020** — Joined Flagship Pioneering as CEO-Partner and Kintai Therapeutics as CEO in July; subsequently led Senda Biosciences.
- **2023** — Named CEO and board member of Sail Biomedicines when Senda and Laronde combined in October.
- **2025** — Announced departure from Sail and Flagship; NextBio’s company profile gives 2025 as its founding year.
- **2026** — NextBio’s public website lists Pfefer as CEO; Prota’s board page lists him as a director.

## Achievements

- Named to the 2021 PharmaVOICE 100.
- Led organizations across multinational pharmaceutical companies and emerging biotech businesses.
- Appointed founding CEO of Sail Biomedicines following the 2023 combination of Senda and Laronde.

## Latest updates

- **2025-01** — Appeared in Flagship’s January 16 CEO Chat as Sail CEO.
- **2025-02** — Announced departure from Sail and Flagship and plans for family time and reflection.

## Links

- Website: https://nextbio.team/
- LinkedIn: https://www.linkedin.com/in/guillaumepfefer

---

Profile page: https://yespress.io/guillaume-pfefer
Published by YesPress — https://yespress.io
Last updated: 2026-10-09